公开(公告)号：US20160193213A1

公开(公告)日：2016-07-07

申请号：US14982322

申请日：2015-12-29

Applicant: Imprimis Pharmaceuticals, Inc.

Inventor： Mark L. Baum

IPC: A61K31/522 ,  A61K45/06 ,  A61K9/00

CPC classification number: A61K31/522 ,  A61K9/0019 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61P17/02 ,  A61P21/00 ,  A61P27/06 ,  A61P43/00

Abstract: Pharmaceutical compositions and methods for treating various diseases and pathologies, such as Dupuytren contracture, are described, the compositions comprising pentoxifylline and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them are also described.

Abstract translation: 描述了用于治疗各种疾病和病理学的药物组合物和方法，例如Dupuytren挛缩，组合物包含己酮可可碱和药学上可接受的载体。 还描述了制备组合物并使用它们的方法。

公开(公告)号：US20140249145A1

公开(公告)日：2014-09-04

申请号：US13991816

申请日：2011-12-08

Applicant: Juan Jose Marugan ,  Noel Southall ,  Ehud Goldin ,  Wei Zheng ,  Samarjit Patnaik ,  Ellen Sidransky ,  Omid Motabar ,  Wendy Westbroek

Inventor： Juan Jose Marugan ,  Noel Southall ,  Ehud Goldin ,  Wei Zheng ,  Samarjit Patnaik ,  Ellen Sidransky ,  Omid Motabar ,  Wendy Westbroek

IPC: C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61P43/00 ,  C07D487/04

Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.

Abstract translation: 本文描述了取代的吡唑并嘧啶和二氢吡唑并嘧啶及其相关化合物，其制备方法，含有这些化合物的组合物，以及这些化合物在治疗溶酶体贮积症如戈谢病中的应用方法。 化合物是通式（I），其中变量R1-R7和X在本申请中描述。

公开(公告)号：US20130209424A1

公开(公告)日：2013-08-15

申请号：US13837265

申请日：2013-03-15

Applicant: Children's Medical Center Corporation ,  The General Hospital Corporation

Inventor： Leonard I. Zon ,  Trista E. North ,  Wolfram Goessling

IPC: A61K35/28 ,  A61K45/06

CPC classification number: A61K35/14 ,  A61K31/575 ,  A61K35/28 ,  A61K35/50 ,  A61K45/06 ,  A61P43/00 ,  C12N5/0647 ,  C12N2501/02

Abstract: The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.

Abstract translation: 本发明提供了通过使用HCS调节剂调节造血干细胞群体的组合物和方法，所述HCS调节剂是根据特定适应症所希望的增加HSC数量或降低HSC数量的药剂。 例如，发现增加HSC数量的HSC调节剂包括前列腺素E2（PGE2）和刺激PGE2途径的试剂。 相反，防止PGE2合成的HSC调节剂降低HSC数。 HCS调节剂可以在体外，体内或体外使用。

公开(公告)号：US20130149396A1

公开(公告)日：2013-06-13

申请号：US13758660

申请日：2013-02-04

Applicant: HS Pharmaceuticals, LLC

Inventor： Richard Thomas Stanley, SR. ,  David Edward Stanley

IPC: A61K33/00

CPC classification number: A61K33/00 ,  A61K31/70 ,  A61P31/00 ,  A61P31/04 ,  A61P31/18 ,  A61P31/22 ,  A61P43/00 ,  Y02A50/385 ,  Y02A50/411

Abstract: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Abstract translation: 本发明涉及包含硅酸盐的组合物及其使用方法。 特别地，本发明的组合物适用于治疗炎性病症，癌症，细菌和病毒感染以及感染和未感染的伤口。 本发明的组合物还可用于治疗脊髓损伤，组织重塑和促进骨生长和修复。

公开(公告)号：US20100099645A1

公开(公告)日：2010-04-22

申请号：US11920914

申请日：2006-05-23

Applicant: Richard J. Wurtman ,  Ingrid Richardson

Inventor： Richard J. Wurtman ,  Ingrid Richardson

IPC: A61K31/7072 ,  A61K31/506 ,  A61K31/675 ,  A61P25/00

CPC classification number: A61K31/7072 ,  A61K31/14 ,  A61K31/202 ,  A61P25/00 ,  A61P25/28 ,  A61P43/00 ,  A61K2300/00

Abstract: This invention provides methods of increasing or enhancing the synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell; methods of treating a subject with a memory disorder, memory impairment, neurological disorder, or brain disease or disorder, comprising administering to the subject a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, uridine, a metabolic precursor thereof, or a combination thereof.

Abstract translation: 本发明提供了通过神经细胞或脑细胞增加或增强磷脂，突触，突触蛋白和突触膜的合成和水平的方法; 治疗记忆障碍，记忆障碍，神经障碍或脑疾病或病症的受试者的方法，包括向受试者施用包含ω-3脂肪酸，ω-6脂肪酸，尿苷及其代谢前体的组合物 ，或其组合。

公开(公告)号：US20240360231A1

公开(公告)日：2024-10-31

申请号：US18589200

申请日：2024-02-27

Applicant: AstraZeneca AB

Inventor： Catharina LINDHOLM ,  Yen Lin CHIA ,  Rajendra TUMMALA ,  Lorin ROSKOS ,  Joachim ALMQUIST ,  Tomas ROUSE

IPC: C07K16/28 ,  A61K39/00 ,  A61P37/06 ,  A61P43/00

CPC classification number: C07K16/2866 ,  A61P37/06 ,  A61P43/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.

公开(公告)号：US20240350527A1

公开(公告)日：2024-10-24

申请号：US18685067

申请日：2022-08-22

Applicant: AIM ImmunoTech Inc.

Inventor： Thomas K. EQUELS ,  David R. STRAYER

IPC: A61K31/713 ,  A61P43/00 ,  C12N15/117

CPC classification number: A61K31/713 ,  A61P43/00 ,  C12N15/117

Abstract: Disclosed is a method for treating a subject that has previously been infected with SARS-COV-2 and exhibiting at least one Post COVID-19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

公开(公告)号：US12116592B2

公开(公告)日：2024-10-15

申请号：US17385560

申请日：2021-07-26

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Mariusz Z. Ratajczak ,  Janina Ratajczak ,  Magdalena Kucia ,  Donald Miller

IPC: A61K35/28 ,  A61K31/19 ,  A61K38/09 ,  A61P43/00 ,  C12N5/0735 ,  C12N5/0775 ,  C12N15/113

CPC classification number: C12N5/0606 ,  A61K31/19 ,  A61K35/28 ,  A61K38/09 ,  A61P43/00 ,  C12N5/0665 ,  C12N15/113 ,  C12N2500/38 ,  C12N2501/15 ,  C12N2501/31

Abstract: Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.

公开(公告)号：US12110325B2

公开(公告)日：2024-10-08

申请号：US18154597

申请日：2023-01-13

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Se Mi Kim ,  Jung Weon Lee ,  Dongjoon Ko ,  Junghwa Yoon ,  Eunmi Kim ,  Seo Hee Nam ,  Eun Ae Shin

IPC: C07K16/28 ,  A61P43/00 ,  C12N15/63

CPC classification number: C07K16/28 ,  A61P43/00 ,  C12N15/63 ,  C07K2317/565

Abstract: The present disclosure relates to TM4SF5-specific humanized antibodies and uses thereof.

公开(公告)号：US20240299416A1

公开(公告)日：2024-09-12

申请号：US18655576

申请日：2024-05-06

Applicant: ReveraGen BioPharma, Inc.

Inventor： Jesse DAMSKER ,  Eric HOFFMAN

IPC: A61K31/573 ,  A61K9/00 ,  A61K9/10 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P21/00 ,  A61P43/00

CPC classification number: A61K31/573 ,  A61K9/0053 ,  A61K9/10 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P21/00 ,  A61P43/00

Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.